The special dividend and buyback provide immediate cash returns, while insider buying adds credibility. Monitor pipeline milestones for ifetroban as the company transitions to a development-stage biopharma with no near-term commercial revenue.
Price Chart
Executive Summary
Cumberland Pharmaceuticals declared a special dividend of $1.50 per share and authorized a $5M buyback, returning capital from the $100M Apotex Health transaction. Insider purchase plans signal management confidence, while the company retains its ifetroban pipeline for rare diseases.
Key Financial Metrics
Key Facts
- Special cash dividend of $1.50 per share, payable July 31, 2026 to holders of record July 10, 2026.
- Board authorized open-market share repurchase program of up to $5 million.
- Several board members establishing new share purchase plans to increase holdings.
- Company received $100 million in cash from closing of strategic transaction with Apotex Health.
- Company retains ifetroban pipeline targeting Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis, and Cancer Metastasis.
Financial Impact
Special dividend of $1.50 per share returning substantial cash to shareholders (estimated ~20-30% of market cap); $5M buyback program adds further capital return.
Risk Factors
- Company sold its FDA-approved product line; now relies entirely on pipeline success for future value.
- Ifetroban is in Phase 2; clinical and regulatory risks remain for all indications.
- Special dividend depletes cash reserves, though company states significant liquidity remains.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302823903 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $5.22 | awaiting T+1 | — | $4.35 (−16.67%) |
Oct 23, 2026 3d ago | 8-K | $8.46 | awaiting T+1 | — | $4.35 (−48.58%) |
Aug 28, 2026 8w ago | 8-K | $6.69 $6.56 | ▲ +1.94% | ▲ +1.26% | $4.35 (+34.98%) |
Jul 13, 2026 15w ago | Press Release | $6.54 $6.99 | ▲ +6.80% | ▲ +6.45% | $4.35 (−33.49%) |
May 26, 2026 21w ago | DEFM14A | $5.77 $5.86 | ▲ +1.56% | ▲ +1.55% | $4.35 (−24.61%) |
Apr 23, 2026 26w ago | DEFA14A / 8-K | $3.90 $4.06 | ▲ +4.10% | ▲ +3.32% | $4.35 (+11.54%) |
Mar 9, 2026 33w ago | DEFA14A | $3.16 $3.08 | ▼ −2.53% | ▼ −2.43% | $4.35 (+37.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers